L2 Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

L2 Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$594K	Buy	+952	New	+$648K	0.06%	232
2023 Q4	–	Sell	-22	Closed	-$582K	–	229
2023 Q3	$582K	Sell	22 -1,531	-99%	-$1.2M	0.27%	83
2023 Q2	$1.12M	Sell	1,553 -393	-20%	-$303K	0.55%	55
2023 Q1	$1.6M	Buy	1,946 +558	+40%	+$421K	0.88%	35
2022 Q4	$1M	Hold	1,388	–	–	0.62%	49
2022 Q3	$956K	Buy	1,388 +404	+41%	+$254K	0.66%	50
2022 Q2	$582K	Buy	+984	New	+$640K	0.42%	67

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

L2 Asset Management's REGN Position: Q2 2026 in Review

L2 Asset Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 952 shares worth $594K. The stake represents 0.06% of the portfolio and ranks #232 among its holdings. This is a return to the name: L2 Asset Management previously reported a position in REGN as recently as Q3 2023.

L2 Asset Management first reported a position in REGN in Q2 2022 and has held it in 7 quarters since. The position peaked at $1.6M in Q1 2023. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

L2 Asset Management held 952 shares of Regeneron Pharmaceuticals worth $594K as of Q2 2026.
Regeneron Pharmaceuticals was a new L2 Asset Management position in Q2 2026.
Regeneron Pharmaceuticals made up 0.06% of L2 Asset Management's portfolio in Q2 2026, its #232 holding.
L2 Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2022 and has held it in 7 quarters since.
L2 Asset Management's Regeneron Pharmaceuticals position peaked at $1.6M in Q1 2023.
1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on L2 Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.